4D Molecular Therapeutics Inc [FDMT] stock is trading at $8.76, up 11.45%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FDMT shares have gain 12.74% over the last week, with a monthly amount drifted -19.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
4D Molecular Therapeutics Inc [NASDAQ: FDMT] stock has seen the most recent analyst activity on November 07, 2025, when Morgan Stanley upgraded its rating to a Equal-Weight. Previously, BMO Capital Markets downgraded its rating to Market Perform on January 13, 2025, and dropped its price target to $15. On November 21, 2024, Morgan Stanley initiated with an Underweight rating and assigned a price target of $8 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Barclays initiated its recommendation with an Overweight and recommended $459 as its price target on April 15, 2024. Barclays started tracking with an Overweight rating for this stock on April 15, 2024, and assigned it a price target of $45.
4D Molecular Therapeutics Inc [FDMT] stock has fluctuated between $2.23 and $12.34 over the past year. Currently, Wall Street analysts expect the stock to reach $25.33 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $8.76 at the most recent close of the market. An investor can expect a potential return of 189.16% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
4D Molecular Therapeutics Inc [NASDAQ:FDMT] reported sales of 0.12M for the trailing twelve months, which represents a growth of 2900.00%. Gross Profit Margin for this corporation currently stands at -807.11% with Operating Profit Margin at -1919.83%, Pretax Profit Margin comes in at -1743.14%, and Net Profit Margin reading is -1743.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.47 and Total Capital is -0.6. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, 4D Molecular Therapeutics Inc’s Current Ratio is 8.42. In addition, the Quick Ratio stands at 8.42 and the Cash Ratio stands at 1.31. Considering the valuation of this stock, the price to sales ratio is 4170.84, the price to book ratio is 1.11.
Transactions by insiders
Recent insider trading involved Gupta Ashoo, VP, Finance and Controller, that happened on Dec 20 ’25 when 389.0 shares were sold. Chief Legal Officer, Bizily Scott completed a deal on Dec 16 ’25 to sell 1635.0 shares. Meanwhile, Officer SCOTT BIZILY bought 1635.0 shares on Dec 16 ’25.
